Dr. Tsaioun is Chief Scientific Officer of Cyprotex and is co-editor of the book “ADMET for Medicinal Chemists”, published by Wiley & Sons in 2011. In 2005 she co-founded Apredica, which Cyprotex acquired in 2010 Both Cyprotex and Apredica are contract research organizations specializing in ADME Tox. Combining the companies created the world’s largest specialist ADME Tox company, and the only one with in-house capabilities in both in vitro and in silico ADME Tox.
Cyprotex has operations in the UK and USA, with 70 employees worldwide. At Cyprotex Dr. Tsaioun is driving innovation in in vitro ADME and mechanistic toxicology, and is advancing proprietary computational approaches in PBPK modeling. Prior to founding Apredica, she worked at a number of drug-discovery companies building and leading multidisciplinary drug-discovery teams focused on in vitro ADME. Dr. Tsaioun earned her M.S. degree in solid-state chemistry from the Leningrad Institute of Technology, her Ph.D. from Tufts University, and completed post-doctoral training at the Neurochemistry Department at the Harvard University Primate Center. She serves on the scientific review boards of the Alzheimer’s Drug Discovery Foundation, International Rett Syndrome Foundation, and Safer Medicines Trust.